Thermal ablation plays an important role in the treatment of extrahepatic metastasis of hepatocellular carcinoma (HCC). Yet laser ablation (LA), as a safe thermal ablative modality, is less investigated in this field. In this study, the safety and local effectiveness of LA in the treatment for the extrahepatic metastasis of HCC were evaluated. From May 2012 to May 2019, 17 patients (13 males and 4 females; mean age, 54.1 ± 14.6 years; age range, 34–80 years), who underwent LA for treatment of extrahepatic metastasis of HCC at the First Affiliated Hospital of Sun Yat-sen University, were retrospectively enrolled in this study. Local effectiveness, complications, local tumor progression (LTP), and overall survival (OS) were evaluated. Finally, a total of 28 LA treated extrahepatic metastatic lesions of HCC were reviewed. Neither LA-related mortality nor major complication occurred. Complete ablation (CA) was achieved in 20 out of 28 lesions (71.4%). During the follow-up (mean, 19.5 ± 12.8 months; range, 5–42.7 months), LTP developed in 4 out of 20 lesions with CA (20%). Four patients died of tumor progression or multiple organ dysfunction syndrome. The accumulative one- and three-year OS rates were 79.0% and 65.8%, respectively. In conclusion, LA is a safe and effective therapeutic option in the treatment of extrahepatic metastasis of HCC. Further studies are necessary to evaluate the benefit of LA.

中文翻译：

---

激光消融对肝细胞癌肝外转移的安全性和局部疗效：可用的治疗策略

热消融在肝细胞癌肝外转移的治疗中起着重要作用。然而，作为一种安全的热消融方式，激光消融（LA）在这一领域的研究较少。在这项研究中，评估了LA在治疗HCC肝外转移中的安全性和局部有效性。从2012年5月至2019年5月，有17例患者（男13例，女4例；平均年龄54.1±14.6岁；年龄范围34-80岁）在太阳第一附属医院接受了LA治疗HCC的肝外转移中山大学，本研究进行了回顾性研究。评价局部有效性，并发症，局部肿瘤进展（LTP）和总生存期（OS）。最后，回顾了总共28例LA治疗的肝癌肝外转移性病变。既没有发生LA相关的死亡率，也没有发生重大并发症。28个病变中有20个达到了完全消融（CA）（71.4％）。在随访期间（平均19.5±12.8个月；范围5–42.7个月），在20例CA病变中，有4例发生LTP（20％）。四例患者死于肿瘤进展或多器官功能障碍综合征。一年和三年的累积OS率分别为79.0％和65.8％。总之，LA是治疗HCC肝外转移的安全有效的治疗选择。评估LA的益处还需要进一步的研究。四例患者死于肿瘤进展或多器官功能障碍综合征。一年和三年的累积OS率分别为79.0％和65.8％。总之，LA是治疗HCC肝外转移的安全有效的治疗选择。评估LA的益处还需要进一步的研究。四例患者死于肿瘤进展或多器官功能障碍综合征。一年和三年的累积OS率分别为79.0％和65.8％。总之，LA是治疗HCC肝外转移的安全有效的治疗选择。评估LA的益处还需要进一步的研究。